Table 5 Specific PIMs and PPOs according to STOPP/START criteria
PIM | Drug class | Frequency (%) |
|---|---|---|
Using STOPP criteria | ||
 Amitriptyline | TCA anti-depressants | 38 (29.7) |
 Furosemide | Loop diuretics | 27 (21) |
 Glibenclamide | Sulphonyl urea | 18 (14) |
 Enalapril | ACEIs | 12 (9.4) |
 Hydrochlorothiazide’s | Thiazide diuretics | 10 (7.8) |
 Aspirin | Anti-platelet | 8 (6.25) |
 Metformin | Biguanides | 4 (3.1) |
 Clopidogrel | Anti-platelet | 3 (2.3) |
 Digoxin | Digitalis glycosides | 2(1.6) |
 Tramadol | Narcotic analgesics | 2(1.6) |
 Metoprolol | Beta blocker | 2(1.6) |
 Indomethacin | NSAID | 1(0.8) |
 Meloxicam | NSAID | 1(0.8) |
 Total |  | 128 (100) |
Using START criteria (PPOs) | ||
 ACEIs | ACEIs | 14(58.3) |
 Beta-blockers | Beta-blockers | 7(29.2) |
 Aspirin | Anti-platelet | 1(4.2) |
 Non-TCA anti-depressants | Non-TCA antidepressants | 1(4.2) |
 Regular inhaled beta 2 agonist | Regular inhaled beta 2 agonist | 1(4.2) |